Hims & Hers hit by FTC privacy lawsuit, stock drops 14.7% as lead-plaintiff deadline looms

The Federal Trade Commission filed a complaint on July 29, 2026 alleging that Hims & Hers Health (NYSE: HIMS) illegally shared consumers' sensitive health information with third‑party advertisers such as Meta and Snap, and misled users about billing and cancellation practices. The announcement sent HIMS shares tumbling 14.73% on the same day, intensifying scrutiny of the telehealth company's privacy safeguards.

In response, securities litigation firms have opened lead‑plaintiff opportunities for investors who purchased HIMS stock between August 4, 2025 and the FTC filing date, with a filing deadline of November 2, 2026. Multiple alerts from firms such as Kessler Topaz Meltzer & Check and Kaplan Fox underscore the urgency for affected shareholders to consider participation.

Separately, two Hims & Hers officers have filed Rule 144 sale notices. Chief Technology Officer Mohamed Elshenawy plans to sell 7,954 shares valued at about $225,814, tied to shares vesting August 15, 2026. Officer Michael Chi already sold 14,027 shares on June 17, 2026 for about $441,850, tied to a separate June 15, 2026 vesting date. Together the two filings cover 21,981 shares. These disposals, combined with broader market commentary, have coincided with HIMS underperforming its peers, as reflected in a steep decline and negative sentiment on platforms like Stocktwits and Yahoo! Finance.

Despite the headwinds, some analysts continue to highlight potential longer‑term upside tied to HIMS's emerging peptide therapeutics and an anticipated regulatory meeting. Market participants will be watching the outcome of the FTC case, the progress of the peptide pipeline, and any further insider transactions to gauge whether the current discount presents a buying opportunity or a risk‑laden trap.